Morgan Stanley
VTGN icon

Morgan Stanley’s VistaGen Therapeutics VTGN Stock Holding History

Morgan Stanley’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Sell
1
-12,657
-100% -$7.69K ﹤0.01% 8286
2025
Q4 		$8.38K Sell
12,658
-14,876
-54% -$53.7K ﹤0.01% 6930
2025
Q3 		$97.7K Buy
27,534
+15,387
+127% +$46K ﹤0.01% 6163
2025
Q2 		$24.3K Sell
12,147
-39,138
-76% -$88.9K ﹤0.01% 6589
2025
Q1 		$128K Buy
51,285
+34,193
+200% +$96.8K ﹤0.01% 5907
2024
Q4 		$50.4K Buy
17,092
+11,773
+221% +$33.1K ﹤0.01% 6286
2024
Q3 		$16K Sell
5,319
-547
-9% -$1.87K ﹤0.01% 6572
2024
Q2 		$20.4K Sell
5,866
-15,593
-73% -$67.5K ﹤0.01% 6450
2024
Q1 		$113K Sell
21,459
-17,689
-45% -$85.1K ﹤0.01% 5936
2023
Q4 		$201K Buy
39,148
+36,588
+1,429% +$138K ﹤0.01% 5946
2023
Q3 		$13.4K Sell
2,560
-860
-25% -$3.82K ﹤0.01% 6616
2023
Q2 		$6.4K Sell
3,420
-2,685
-44% -$9.41K ﹤0.01% 6928
2023
Q1 		$22.8K Sell
6,105
-2,208
-27% -$11.6K ﹤0.01% 6576
2022
Q4 		$25.7K Buy
8,313
+3,150
+61% +$11.9K ﹤0.01% 6569
2022
Q3 		$24K Buy
5,163
+833
+19% +$8.26K ﹤0.01% 6722
2022
Q2 		$114K Sell
4,330
-19,846
-82% -$701K ﹤0.01% 6205
2022
Q1 		$899K Buy
24,176
+12,730
+111% +$555K ﹤0.01% 5073
2021
Q4 		$669K Buy
11,446
+9,715
+561% +$632K ﹤0.01% 5374
2021
Q3 		$142K Sell
1,731
-5,253
-75% -$456K ﹤0.01% 6184
2021
Q2 		$660K Sell
6,984
-14,068
-67% -$1.04M ﹤0.01% 5346
2021
Q1 		$1.34M Buy
21,052
+20,634
+4,936% +$1.38M ﹤0.01% 4539
2020
Q4 		$24K Hold
418
– – ﹤0.01% 6381
2020
Q3 		$9K Hold
418
– – ﹤0.01% 6310
2020
Q2 		$7K Hold
418
– – ﹤0.01% 6248
2020
Q1 		$6K Hold
418
– – ﹤0.01% 6159
2019
Q4 		$9K Sell
418
-1
-0.2% -$25 ﹤0.01% 6292
2019
Q3 		$13K Sell
419
-2
-0.5% -$45 ﹤0.01% 6136
2019
Q2 		$9K Buy
421
+3
+0.7% +$80 ﹤0.01% 6172
2019
Q1 		$16K Buy
+418
New +$18.2K ﹤0.01% 6079
2018
Q1 		– Sell
-15
Closed – – 6705
2017
Q4 		$0 Buy
+15
New +$495 ﹤0.01% 6659

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley's VTGN Position: Q1 2026 in Review

Morgan Stanley reduced its VistaGen Therapeutics (VTGN) stake by 100% in Q1 2026, selling an estimated $7.69K and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #8286.

Morgan Stanley first reported a position in VTGN in Q4 2017 and has held it in 30 quarters since. The position peaked at $1.34M in Q1 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Morgan Stanley held 1 share of VistaGen Therapeutics worth $1 as of Q1 2026.
  • Morgan Stanley sold 12,657 VistaGen Therapeutics shares in Q1 2026, an estimated $7.69K.
  • VistaGen Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8286 holding.
  • Morgan Stanley first reported a position in VistaGen Therapeutics in Q4 2017 and has held it in 30 quarters since.
  • Morgan Stanley's VistaGen Therapeutics position peaked at $1.34M in Q1 2021.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.